Skip to content
Screener

Jade Biosciences JBIO Total Liabilities & Equity

Total Liabilities & Equity at other companies

Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
$27.42B+14.1%
Climb Global Solutions, Inc. logo
Climb Global Solutions, Inc.CLMB
$458.84M+24.0%
Travere Therapeutics, Inc. logo
Travere Therapeutics, Inc.TVTX
$555.19M+1.2%
Vera Therapeutics logo
Vera TherapeuticsVERA
$621.74M+1.9%
Vor Biopharma logo
Vor BiopharmaVOR
$506.75M+364%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$329.68M-21.9%

Other financials

Income statement

See full
Operating income-$43.4M-85.8%
Net income-$40.4M-5.8%
EPS (diluted)-$0.57+95.3%

Balance sheet

See full
Cash & equivalents$55.1M+24.6%
Total debt$808.0K+159%
Total equity$296.5M+455%
Total assets$319.4M+312%

Cash flow

See full
Operating cash flow-$24.1M-28.4%
CapEx$3.0K
Free cash flow-$33.7M

Valuation

See full
Market cap$1.35B+436%
Enterprise value$1.3B+3,925%

Returns & leverage

See full
Return on equity-132.5%+120pp
Debt / equity
Current ratio14.3×-17.7×

Where this comes from

Reported directly by Jade Biosciences in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesAndStockholdersEquity.

The source filing: Jade Biosciences’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:27 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-212088
Line itemMarch 31,2026December 31,2025
Stockholders’ equity:
Series A non-voting convertible preferred stock, $0.0001 par value; 12,622 shares authorized as of both March 31, 2026 and December 31, 2025; 12,622 shares issued and outstanding as of both March 31, 2026 and December 31, 202522
Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025, respectively; 49,345,967 and 49,316,287 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively55
Additional paid-in capital511,554506,771
Accumulated other comprehensive (loss) income(342)129
Accumulated deficit(214,757)(174,389)
Total stockholders’ equity296,462332,518
Total liabilities and stockholders' equity$319,433$349,781

Item 1. Financial Statements.

FAQ

What is Jade Biosciences's total liabilities & equity?
Jade Biosciences (JBIO) reported total liabilities & equity of $319.43M in Q1 2026.
How has Jade Biosciences's total liabilities & equity changed year-over-year?
Jade Biosciences's total liabilities & equity increased by 312.0% year-over-year, from $77.53M to $319.43M.
What is the long-term trend for Jade Biosciences's total liabilities & equity?
Over 5 years (2020 to 2025), Jade Biosciences's total liabilities & equity has grown at a 136.6% compound annual growth rate (CAGR), from $4.72M to $349.78M.
What does total liabilities & equity mean?
Total assets = total liabilities + total equity. This must always balance — a fundamental accounting identity.

Ask your AI about Jade Biosciences's total liabilities & equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude